DK1200117T3 - Behandling med lipoprotein-lipase (LPL) variant - Google Patents
Behandling med lipoprotein-lipase (LPL) variantInfo
- Publication number
- DK1200117T3 DK1200117T3 DK00943499T DK00943499T DK1200117T3 DK 1200117 T3 DK1200117 T3 DK 1200117T3 DK 00943499 T DK00943499 T DK 00943499T DK 00943499 T DK00943499 T DK 00943499T DK 1200117 T3 DK1200117 T3 DK 1200117T3
- Authority
- DK
- Denmark
- Prior art keywords
- lpl
- lipoprotein
- lipase
- treatment
- variant treatment
- Prior art date
Links
- 108010013563 Lipoprotein Lipase Proteins 0.000 title abstract 5
- 102000043296 Lipoprotein lipases Human genes 0.000 title abstract 3
- 102100022119 Lipoprotein lipase Human genes 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 108010023302 HDL Cholesterol Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 201000011110 familial lipoprotein lipase deficiency Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01034—Lipoprotein lipase (3.1.1.34)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99202048 | 1999-06-24 | ||
| PCT/CA2000/000762 WO2001000220A2 (en) | 1999-06-24 | 2000-06-23 | Lipoprotein lipase (lpl) variant therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1200117T3 true DK1200117T3 (da) | 2008-11-17 |
Family
ID=8240356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00943499T DK1200117T3 (da) | 1999-06-24 | 2000-06-23 | Behandling med lipoprotein-lipase (LPL) variant |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110201673A1 (de) |
| EP (1) | EP1200117B1 (de) |
| JP (1) | JP5095894B2 (de) |
| AT (1) | ATE404217T1 (de) |
| AU (1) | AU5799200A (de) |
| CA (1) | CA2370081C (de) |
| CY (1) | CY1108511T1 (de) |
| DE (1) | DE60039880D1 (de) |
| DK (1) | DK1200117T3 (de) |
| ES (1) | ES2311464T3 (de) |
| PT (1) | PT1200117E (de) |
| WO (1) | WO2001000220A2 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1729824T3 (da) * | 2004-03-02 | 2009-11-02 | Cellectar Inc | Phospholipidanaloger til behandling af cancere |
| WO2005123117A1 (en) * | 2004-06-21 | 2005-12-29 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Treatment of non alcoholic steatotic hepatitis (nash) |
| PT3272872T (pt) | 2005-10-20 | 2020-06-26 | Uniqure Ip Bv | Vetores aav melhorados produzidos em células de insetos |
| CN103849629B (zh) | 2006-06-21 | 2017-06-09 | 尤尼克尔Ip股份有限公司 | 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体 |
| BRPI0814459B1 (pt) | 2007-07-26 | 2023-01-24 | Uniqure Ip B.V | Método para produzir um vírion parvoviral recombinante em uma célula de inseto, e, construção de ácido nucleico |
| WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| EP2432497A1 (de) * | 2009-05-18 | 2012-03-28 | Amsterdam Molecular Therapeutics (AMT) IP B.V. | Verwendung von lipoprotein-lipase (lpl) in der therapie |
| WO2010144788A2 (en) | 2009-06-12 | 2010-12-16 | Cellectar, Inc. | Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer stem cells |
| US9228174B2 (en) | 2010-03-11 | 2016-01-05 | Uniqure Ip B.V. | Mutated rep encoding sequences for use in AAV production |
| WO2011122950A1 (en) | 2010-04-01 | 2011-10-06 | Amsterdam Molecular Therapeutics (Amt) Ip B.V. | Monomeric duplex aav vectors |
| KR102063195B1 (ko) | 2012-02-07 | 2020-01-07 | 글로벌 바이오 테라퓨틱스, 인크. | 핵산 전달의 구획화된 방법 및 이의 조성물 및 용도 |
| EP3052106A4 (de) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynukleotide zur codierung immunmodulierender polypeptide |
| SG11201602503TA (en) | 2013-10-03 | 2016-04-28 | Moderna Therapeutics Inc | Polynucleotides encoding low density lipoprotein receptor |
| UA120923C2 (uk) | 2014-03-10 | 2020-03-10 | Юнікьюре Айпі Б.В. | Молекула нуклеїнової кислоти, яка кодує капсидний протеїн aav5 |
| MA41035A (fr) | 2014-08-19 | 2017-08-15 | Shire Human Genetic Therapies | Lipoprotéine lipase pour le traitement d'affections liées à une hypertriglycéridémie, y compris la pancréatite aiguë |
| EP3458106A4 (de) * | 2016-05-18 | 2020-03-18 | Modernatx, Inc. | Polynukleotide zur codierung von lipoproteinlipase zur behandlung von hyperlipidämie |
| US10286087B2 (en) | 2016-12-16 | 2019-05-14 | Uniqure Ip B.V. | Immunoadsorption |
| JP2020526203A (ja) | 2017-07-10 | 2020-08-31 | ユニキュアー アイピー ビー．ブイ． | ヒトにおけるａａｖ遺伝子療法のための手段及び方法 |
| JP2020532286A (ja) | 2017-07-20 | 2020-11-12 | ユニキュアー アイピー ビー．ブイ． | 昆虫細胞における向上したａａｖカプシド産生 |
| CA3084452A1 (en) | 2017-12-29 | 2019-07-04 | Uniqure Ip B.V. | Modified viral vectors and methods of making and using the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0755268A1 (de) * | 1994-04-11 | 1997-01-29 | Baylor College Of Medicine | Zusammensetzungen und verfahren zur behandlung von erkrankungen durch gentherapie |
| US5658729A (en) * | 1994-10-11 | 1997-08-19 | The University Of British Columbia | Method, reagent and kit for evaluating susceptibility to premature atherosclerosis |
-
2000
- 2000-06-23 AT AT00943499T patent/ATE404217T1/de active
- 2000-06-23 JP JP2001505929A patent/JP5095894B2/ja not_active Expired - Fee Related
- 2000-06-23 CA CA2370081A patent/CA2370081C/en not_active Expired - Fee Related
- 2000-06-23 AU AU57992/00A patent/AU5799200A/en not_active Abandoned
- 2000-06-23 ES ES00943499T patent/ES2311464T3/es not_active Expired - Lifetime
- 2000-06-23 DK DK00943499T patent/DK1200117T3/da active
- 2000-06-23 WO PCT/CA2000/000762 patent/WO2001000220A2/en active IP Right Grant
- 2000-06-23 DE DE60039880T patent/DE60039880D1/de not_active Expired - Lifetime
- 2000-06-23 EP EP20000943499 patent/EP1200117B1/de not_active Expired - Lifetime
- 2000-06-23 PT PT00943499T patent/PT1200117E/pt unknown
-
2008
- 2008-11-13 CY CY20081101305T patent/CY1108511T1/el unknown
-
2010
- 2010-10-05 US US12/898,684 patent/US20110201673A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE404217T1 (de) | 2008-08-15 |
| CA2370081C (en) | 2014-06-03 |
| EP1200117B1 (de) | 2008-08-13 |
| WO2001000220A2 (en) | 2001-01-04 |
| CY1108511T1 (el) | 2014-04-09 |
| AU5799200A (en) | 2001-01-31 |
| PT1200117E (pt) | 2008-11-26 |
| CA2370081A1 (en) | 2001-01-04 |
| DE60039880D1 (en) | 2008-09-25 |
| US20110201673A1 (en) | 2011-08-18 |
| JP2003503355A (ja) | 2003-01-28 |
| ES2311464T3 (es) | 2009-02-16 |
| WO2001000220A3 (en) | 2001-07-12 |
| EP1200117A2 (de) | 2002-05-02 |
| JP5095894B2 (ja) | 2012-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1200117T3 (da) | Behandling med lipoprotein-lipase (LPL) variant | |
| ATE462006T1 (de) | Isoform des vegfs | |
| ATE376591T1 (de) | Neisseria meningitidis antigene und zusammenstellungen | |
| EP1918300A3 (de) | Auf Peptiden basierende Immunisierungstherapie zur Behandlung von Atherosklerose | |
| EA200401471A1 (ru) | Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов | |
| DK0966465T3 (da) | Inhibitorer af IMPDH-enzymer | |
| DE60032367D1 (de) | Aktivierbare rekombinante neurotoxine | |
| DE69905476D1 (en) | Phosphonsaürederivate als ptp-1b-inhibitoren | |
| DE50113396D1 (de) | System zur gezielten Deformation von optischen Elementen | |
| DE69834267D1 (de) | Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen | |
| DE69636453D1 (de) | Modulation der aktivität des cholesteryl-ester-transfer-proteins (cetp) | |
| ATE300619T1 (de) | Humane checkpointkinase, hcds1, zusammensetzungen und verfahren | |
| DE60023860D1 (de) | Verfahren zur herstellung von rekombinanten peptiden | |
| DK1908772T3 (da) | Polypeptider og polynucleinsyrer af phorphorymonas gingivalis | |
| EA200000519A1 (ru) | 2-АРИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ | |
| DE69826717D1 (de) | Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii | |
| SE9604439D0 (sv) | New receptor | |
| WO2001044514A3 (en) | Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements | |
| EP1462518A4 (de) | Mit fettzellendifferenzierung assoziiertes gen und protein | |
| WO2002048312A3 (en) | Backbone cyclized inhibitors of heat shock proteins |